Remote inspections may be handy when the pandemic prevents travel, but they are no substitute for onsite inspections, especially when detailed observations are required, the International Coalition of Medicines Regulatory Authorities has concluded.
A 13 December policy paper that a working group in ICMRA’s COVID-19 group wrote found that while remote inspections are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?